Oral Purified Microbiome Therapy: GI Impact & Benefits
- Okay, here's a breakdown of the methods described in the provided text, organized for clarity.
- * Purpose: To determine how fatty acids inhibit the growth of C.
- * Purpose: To quantify the production of specific metabolites (DCA, LCA, butyrate, hexanoate, and valerate) in VOS (presumably a fecal microbiota transplant product) dose material.
Okay, here’s a breakdown of the methods described in the provided text, organized for clarity. I’ll cover the C. difficile experiments, the VOS dose material analysis, and the statistical methods.
1. Clostridioides difficile Growth Inhibition Assays
* Purpose: To determine how fatty acids inhibit the growth of C. difficile.
* Strains Used: Three different C. difficile ribotypes were tested:
* RT-001
* C. difficile ATCC 9689
* RT-060, C. difficile ATCC 43593
* RT-087, clostridioides difficile ATCC 43255
* Method:
* C. difficile was grown in the presence of eight different concentrations of fatty acids.
* Growth was measured by optical density at 600 nm (OD600).
* Half-maximal inhibitory concentration (IC50) values were calculated from growth curves.
* Each IC50 value is an average of three replicate cultures.
2.VOS Dose Material Metabolite analysis
* Purpose: To quantify the production of specific metabolites (DCA, LCA, butyrate, hexanoate, and valerate) in VOS (presumably a fecal microbiota transplant product) dose material.
* VOS Material: Material from five different batches was used, originating from four donors (one donor contributed to two batches).
* Method:
* VOS material was grown in a complex liquid medium across a 10-fold dilution series (eight dilutions in triplicate).
* Cultures were grown for 5 days.
* Supernatant was collected and analyzed for metabolite concentrations using LC-MS/MS (by Metabolon,Inc.).
* Initial metabolite concentrations (at time 0) were subtracted from final concentrations to account for the media composition.
* The highest measured concentration for each metabolite is reported.
3. Statistical Analyses
* Overall Focus: Analyzing microbiome changes (species engraftment, composition, and bile acid concentrations) in VOS-treated patients compared to placebo.
* Data Points: Measurements were taken at baseline, and at weeks 1, 2, 8, and 24.
* Population: The primary analysis used the “safety population” (patients randomized,received study drug,and provided stool samples before and after treatment).
* Methods:
* Non-parametric median and interquartile range statistics were used to describe engraftment and bile acid measurements.
* The presented analyses are post hoc (meaning they were done after the initial planned analyses) but are consistent wiht the preplanned statistical approach.
* Deviation from Preplanned Analysis: Stool samples collected after treatment of a C. difficile infection recurrence were excluded from these post hoc analyses.
Key Terms/Abbreviations:
* VOS: Likely refers to the oral microbiome therapy being studied (SER-109, as mentioned in reference 12).
* DCA: Deoxycholic acid (a bile acid)
* LCA: Lithocholic acid (a bile acid)
* LC-MS/MS: Liquid Chromatography-tandem Mass Spectrometry (a technique for identifying and quantifying metabolites)
* OD600: Optical density at 600 nm (a measure of bacterial growth)
* IC50: Half-maximal inhibitory concentration (the concentration of a substance that inhibits a biological process by 50%)
* RT: Ribotype (a strain typing method for C. difficile)
* ATCC: American Type Culture Collection (a repository of biological materials)
* CDI: Clostridioides difficile infection
Let me know if you’d like me to elaborate on any specific aspect of these methods!